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Background: IL-33, an IL-1-like cytokine, is a ligand for IL1RL1, which is an important effector molecule of type 2 T
helper responses. Although IL-33/IL1RL1 interaction has been suggested to be important in the development of
atherosclerosis, genetic influences of the polymorphisms of IL33 in human ischemic stroke are unclear. The aim of
this study was to examine whether the single nucleotide polymorphisms in IL33 are associated with ischemic stroke
in Northern Chinese population.
Methods: We used a nested case–control study involving 90 ischemic stroke patients and 270 age-matched, sex-
matched and blood pressure-matched non-ischemic stroke controls from a rural population and determined the
genotypes of four polymorphisms (rs1929992, rs10975519, rs4742170, rs16924159) in IL33 by Snapshot SNP
genotyping assays to assess any links with ischemic stroke.
Results: Univariate analysis showed two single nucleotide polymorphisms (rs1929992, rs4742170) in IL33 were
associated with ischemic stroke in additive, dominant, and recessive model. Binary Logistic Regression shows that
rs4742170 variation is the most important factor associated with ischemic stroke (adjusted odds ratio (OR) = 1.880,
95% confidence interval (CI) = 1.316-2.686 in an additive model; OR = 2.091, CI = 1.249-3.498 in a dominant model;
OR = 2.623, CI = 1.366-5.036 in a recessive model).
Conclusion: In this sample of patients, genetic variation of rs4742170 in IL33 is significantly associated with the
developing of ischemic stroke.
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Ischemic stroke is a common adult disability with high
mortality and severe morbidity [1]. In China, the death
caused by ischemic stroke account for approximately two-
thirds of all death caused by strokes [2]. High blood pres-
sure, hypercholesterolaemia and diabetes are considered
as the main risk factors of ischemic stroke. Inflammation
has also been demonstrated to play an important role in
the development and progression of cardio-cerebral vascu-
lar disease. Local humoral and cellular immune responses
modulate the inflammatory processes involved in the
development of atherosclerotic lesions, as well as in the
evolution of brain infarcts in stroke patients.* Correspondence: sunyingxian12@126.com
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reproduction in any medium, provided the orAlthough the etiology and mechanisms of ischemic
stroke is not clear, it is considered that genetic compo-
nents play a significant role in the pathogenesis of is-
chemic stroke [3]. Genetic variation is an important
factor causing ischemic stroke [4]. The risk of ischemic
stroke can be influenced by genetic variation in the
inflammatory agents, including Interleukin-33 (IL-33),
interleukin 4 (IL-4), interleukin 6 (IL-6), intercellular
adhesion molecule 1 (ICA M-1), E-selectin (E-sel), che-
mokine (C-C motif ) ligand 11 (CCL11), lymphotoxin
(LTA) [1,5,6].
IL-33, also known as IL-1 family member 11, is a
member of the IL-1 cytokine family. IL-33 is a ligand for
Interleukin-1 receptor-like 1(IL1RL1), that is expressed
mainly on activated Th2 cells and mast cells [6-8]. IL-33
is a therapeutic target as a proinflammatory mediator. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cardio-cerebral vascular disease [9,10]. In addition, IL-33
expression is decreased and consistently restricted to
vascular capillaries in the brain of Alzheimer’s disease
(AD) cases [11]. The genes encoding for IL-33 are both
affected by common, functionally important, genetic
polymorphisms, and several genetic polymorphisms have
been considered to associate with AD and cedar pollinosis
[11-14]. Until now, three SNPs (rs1157505, rs11792633,
and rs7044343) in IL33 gene have been reported to be as-
sociated with risk of AD in modulating cerebral amyloid
angiopathy (CAA) formation in Caucasian populations.
Furthermore, another study reports that rs11792633 poly-
morphism is still strongly associated with LOAD in Han
Chinese. These polymorphisms lead to a specific decrease
CAA in the brain of non-APOE ε4 AD cases. Although
several reports suggest that polymorphisms in IL-33 gene
play important roles in the development of cardio-cerebral
vascular disease, the association of polymorphisms of IL33
with human ischemic stroke is still unclear.
In this study, the IL33 gene polymorphisms associated
with history of ischemic stroke in North Chinese pa-
tients were evaluated. Four polymorphisms (rs1929992,
rs10975519, rs4742170, rs16924159) in IL33 gene were
selected by Snapshot SNP genotyping assays, and then
we analyzed the association between the four SNPs and
the risk of ischemic stroke.
Method
Study population
This study was a large-scale cross-sectional epidemio-
logical survey which was conducted in rural areas of
Fuxin Country, Liaoning Province from 2004 to 2006.
The methodology was described previously in detail
[15,16]. A total of 6104 participants with hypertension
(Blood pressure≥140/90) were recruited from 6 geograph-
ical regions in northern China. Ninety patients who suf-
fered an ischemic stroke during a mean follow-up of 6.8
years were eligible to participate in this study. All patients
had medical records of diagnosis based on brain computed
tomography (CT)/MRI. Control subjects were selected
in a ratio of 1:3 according to the case-control study cri-
teria during the same period (control subjects matched
for gender, age within 3 years, geographic location, and
blood pressure category (<160/100, ≥160/100 and ≤180/
110, >180/110 mmHg)). The research protocol was ap-
proved by China Medical University Research Ethics
Committee and written informed consent was obtained
from all patients or their guardians.
Selection of SNPs and genetic analyses
IL33 gene Polymorphisms were selected by Snapshot
SNP genotypin. Haplotype block analysis was performed
by Hapmap phase genotype data for the chromosomalregion 9:6215786.6257983 (CHB database, Hapmap re-
lease #27). And linkage disequilibrium analysis was
conducted using Haploview software (http://www.broad.
mit.edu/mpg/haploview). The selection of tagSNPs was
performed by running the tagger program implemented in
Haploview. The criteria for r2 was set at > 0.7. It indicated
that any marker that was not eventually chosen as a tag-
ging marker was considered strongly correlated with at
least one of the tagging markers with r2 > 0.7. Venous
blood of patients was previously collected by venepunc-
ture. Genomic DNA was extracted using the QIAamp
DNA kit (Qiagen, Hilden, Germany). Genotyping was
performed by multiplex SNaPshot technology using an
ABI fluorescence-based assay discrimination method (Ap-
plied Biosystems, Foster city, CA, USA), which had been
described in detail in previous studies [17,18]. Our assay
was based on multiplex SNaPshot method. The IL33 poly-
morphisms were identified by polymerase chain reaction
(PCR) as previously described [19]. Detection of single-
base extended probe primers was based on fluorescence
and extended length detected by capillary electrophoresis
on ABI3730XL Sequencer (Applied Biosystems, Foster
City, CA, USA).
Statistical analysis
The software SPSS for Windows, version 11.5, was used for
statistical analysis. Continuous variables were expressed as
mean ± SD. Data of differences between case and control
groups were compared by t test. Categorical variables were
presented as percentage. The χ2 or exact test was used
to evaluate significant deviation from Hardy-Weinberg
equilibrium. Then differences in genotype distribution
of the polymorphism between case and control subjects
were compared by a 2×2 contingency χ2 test with one
degree of freedom. Logistic regression analysis was used
to evaluate the association between genotype of SNPs and
ischemic stroke. Three models were used for statistical
analysis, including dominant model (Hz- homozygote,
Het- heterozygote; for isolated SNPs: Hz(rare) + Het vs.
Hz(common); for haplotypes: at least 1 of the indicated
haplotypes vs. all other haplotypes), the recessive genetic
model (for isolated SNPs: Hz rare vs. Het + Hz common;
for haplotypes: 2 of the indicated haplotypes vs. all other
haplotypes) and the additive model. The polymorphisms
of p values were evaluated by a stepwise forward condi-
tional logistic regression analysis in each additive model,
dominant model, and recessive model, respectively. Odds
ratios (ORs) were calculated with 95% CI. A p value of less
than 0.05 was considered statistically significant.
Results
Clinical characteristics of all the subjects in the present
study were shown in Table 1. There were no significant
differences between ischemic stroke group and control






Mean age, year ± SD 62.5 ± 8.5 62.1 ± 8.5 0.743
body mass index (BMI), mean ± SD 23.2 (3.0) 23.7 (4.0) 0.278
Male sex, absolute number (%) 53 (58.9) 159 (58.9) 1
Blood pressure (BP) class 3, no. (%) 30 (33.3) 89 (33) 0.948
BP controlled to below 140/90mmHg (%) 19 (21.1) 62 (23.0) 0.716
Diabetes, absolute number (%) 11 (12.2) 34 (12.6) 0.927
Hyperlipidemia, absolute number (%) 40 (44.4) 104 (38.8) 0.345
Current smoking, absolute number (%) 49 (54.4) 128 (47.4) 0.247
Drinking, absolute number (%) 33 (36.7) 96 (35.6) 0.849
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percentage of diabetes, hyperlipidemia, smoking, drinking,
and lower education (P > 0.05). The percentage of high BP
which was controlled to levels below 140/90 mm Hg was
also similar between the two groups (P = 0.716).
Genotype information of a total of 36 polymorphisms with
a frequency >0.10 in IL33 was derived from the HapMap
CHB populations (http://hapmap.ncbi.nlm.nih.gov/cgi-perl/
gbrowse/hapmap27_B36/). Pairwise LD among the 36 SNPs
was measured with the Haploview 4.2 program (Figure 1).
We finally selected polymorphism rs4742170, rs1929992,Figure 1 Pairwise linkage disequilibrium between 36 SNPs as measur
HapMap CHB data set. The boxed polymorphisms, rs4742170, rs1929992,rs10975519 and rs16924159 for association studies using
tagger in the Haploview 4.2 program, and these four SNPs
captured 36 of 36 alleles with a mean r2 of 0.95. Locations
and Minor Allele Frequencies of the four SNPs were
showed in Table 2.
The genotype distribution of the IL33 gene SNPs in
both groups were shown in Table 3. In univariate ana-
lysis, the rs4742170 was significantly associated with
ischemic stroke in the additive model, the dominant
model and recessive model (additive p: 0.002, dominant
p: 0.005, recessive p: 0.003). Furthermore, the rs1929992
also showed significantly association with ischemic stroke
in the dominant model and recessive model (additive
p: 0.025, dominant p: 0.054, recessive p: 0.014). However,
the rs10975519 was associated with the risk of ischemic
stroke only in the recessive model (additive p: 0.061, dom-
inant p: 0.075, recessive p: 0.040), and the rs16924159
showed no association with ischemic stroke (additive
p: 0.028, dominant p: 0.078, recessive p: 0.472). Then
rs4742170 in IL33 gene was selected for further studies.
As shown in Table 4, after adjustment for Binary
Logistic Regression, the rs4742170 polymorphism was
still significant in three models (adjusted odds ratio
(OR) = 1.880, 95% confidence interval (CI) = 1.316-
2.686, p value=0.001 in an additive model; OR = 2.091,
95% CI = 1.249-3.498, p value=0.005 in a dominanted by r2 estimated by the Haploview 4.2 program using the
rs10975519 and rs16924159, were genotyped in this study.
Table 2 Locations and minor allele frequencies (MAF) of
polymorphisms in IL33
Name Alleles MAF Position
rs16924159 G:A 0.349 5’-Flanking region
rs4742170 T:C 0.464 Intron 1
rs1929992 A:G 0.489 Intron 3
rs10975519 C:T 0.463 Exon 5
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Discussion
This study analyzed SNPs in the IL33 gene in Chinese
patients with ischemic stroke for the first time. We
investigated four SNPs in IL33 gene (rs4742170, rs1929992,
rs10975519, rs16924159), and discovered two SNPs
(rs4742170, rs1929992) were significantly associated
with ischemic stroke at univariate analysis. Moreover,
the rs4742170 polymorphism remained significant as-
sociation with ischemic stroke in three models after
adjustment for Binary Logistic Regression.
Many studies have reported that IL-33 could support
Th2 cells, reduce macrophage foam cell formation and,
probably, modulate endothelial cell function [20,21],
which may play important roles in the series of events
involve in the pathogenesis and development of stroke.
Recently, it has been reported that IL-33/ST2 pathway
can protect against atherosclerosis and adipose tissue
inflammation which are well-known risk factors for ische-
mic stroke [21].Table 3 Association between SNPs and risk for development
additive, dominant, and recessive model
Genotype Case(n=90) Control(n=270
rs1929992
GG, absolute number (%) 28(31.1) 115(42.6)
AG, absolute number (%) 41(45.6) 121(44.8)
AA, absolute number (%) 21(23.3) 34(12.6)
rs10975519
TT, absolute number (%) 25(27.8) 103(38.1)
CT, absolute number (%) 44(48.9) 129(47.8)
CC, absolute number (%) 21(23.3) 38(14.1)
rs4742170
TT, absolute number (%) 26(28.9) 124(45.9)
CT, absolute number (%) 45(50.0) 121(44.8)
CC, absolute number (%) 19(21.1) 25(9.3)
rs16924159
GG, absolute number (%) 52(57.8) 127(47.0)
AG, absolute number (%) 31(34.4) 115(42.6)
AA, absolute number (%) 7(7.8) 28(10.4)In this study, we reported the significant association
of the rs4742170 SNP in IL33 with ischemic stroke in
Chinese population for the first time. Several studies
have demonstrated the gene variation of IL33 is associ-
ated with some cardiovascular and cerebrovascular dis-
eases. Sakashita et al. indicate that SNP of rs1929992 in
IL33 gene is significantly associated with cedar pollino-
sis [13]. In addition, J Chapuis et al reports IL-33 expres-
sion is decreased in Alzheimer’s disease(AD) patients, and
confirm that alleles of three SNPs in IL33gene (rs1157505,
rs11792633 and rs704343) are associated with AD in
Caucasian populations; moreover, genetic variations of
IL33 are associated with a lesser degree of CAA, which
contains mainly Aβ40, and the local secretion of Aβ40
may be a key determinant of AD pathology [11]. Moreover,
the study of Jin-Tai Yu has shown that the minor allele
of the rs11792633 polymorphism in IL33 is significantly
associated with a reduced risk of LOAD in Chinese pa-
tients [14]. These studies suggest that the characterization
of IL-33 as a genetic determinant of AD indicates a poten-
tial relevant link between CAA formation, neurovascular
dysfunction, alteration of immune cell functions and in-
flammatory process, and all of these contribute to AD.
However, it is not clear how genetic variants in IL33 might
affect its function to reduce the risk of ischemic stroke.
Nevertheless, our study also had some limitations.
First, it is a case-control study, all the participants in
this study were Chinese people, and the possibility of
ethnicity as a confounding factor could be excluded. In-
deed, samples should be included subjects from differ-
ent geographical and racial backgrounds which couldof ischemic stroke for northern Chinese population in





Table 4 Associated between rs4742170 variation with
ischemic stroke in additive, dominant, and recessive
model after adjustment for Binary Logistic Regression
Wald p value OR
Additive 12.032 .001 1.880 (1.316 −2.686)
dominant 7.882 .005 2.091 (1.249 −3.498)
recessive 8.390 .004 2.623 (1.366 −5.036)
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performed to assay the functional consequences of genetic
variation in individual patients, such as plasma or tissue
levels of IL-33, and the association between SNPs in IL33
and ischemic stroke is conjectural. Thirdly, the degree of
atherosclerosis was not quantified in the subjects. Finally,
the results of this study are based on a single-center
experience and a small number of patients and must be
viewed as preliminary and our results should be confirmed
in larger samples and should be tested in groups of differ-
ent geographical and racial backgrounds. Thus, further
replication studies will be necessary to evaluate the associ-
ation between the polymorphisms in IL33 gene and the
risk of ischemic stroke.
Conclusion
In conclusion, our findings supported genetic variation of
rs4742170 in IL33 gene as a modest protective factor for
ischemic stroke in North Chinese, and provided further
contribution toward new opportunities to investigate is-
chemic stroke pathogenesis, treatment, and prevention.
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